Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic laxative: PEG-3350 retains water in stool via osmotic effect; electrolytes (potassium, sodium, bicarbonate) prevent electrolyte depletion and maintain fluid balance.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Bowel cleansing prior to colonoscopy,Treatment of occasional constipation (OTC use)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Adult dose for colonoscopy preparation: 240 m L (1 glass) orally every 10 minutes until 4 L consumed or rectal effluent is clear. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water orally once daily, not to exceed 7 days.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
The terminal elimination half-life of PEG-3350 is approximately 1.5 hours for the absorbed fraction; the majority is not absorbed and has negligible systemic half-life. Electrolytes have variable half-lives: potassium ~12 hours (renal function dependent), sodium ~6 hours, chloride ~8 hours, bicarbonate ~15 minutes.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
PEG-3350 is not significantly metabolized; excreted unchanged in feces. Electrolytes are absorbed and regulated by renal function.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
PEG-3350 is eliminated essentially unchanged in feces; less than 1% is absorbed and excreted renally. Electrolytes are absorbed and distributed; potassium is primarily excreted renally (90%), sodium and chloride are excreted renally with regulation by aldosterone, and bicarbonate is converted to CO2 and excreted via lungs.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
PEG-3350: negligible binding. Potassium: none. Sodium: none. Chloride: none. Bicarbonate: negligible binding.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
PEG-3350: Vd approximately 0.1 L/kg (confined to extracellular fluid). Potassium: 0.04 L/kg (primarily intracellular, but distribution is tightly regulated). Sodium: 0.4 L/kg (extracellular). Chloride: 0.2 L/kg (extracellular). Bicarbonate: 0.3 L/kg (extracellular).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
PEG-3350: <0.1% absorbed orally; essentially negligible systemic bioavailability. Electrolytes: potassium chloride (100% absorbed), sodium chloride (100% absorbed), sodium bicarbonate (100% absorbed).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose adjustment for GFR; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to risk of electrolyte disturbances; monitor electrolytes and fluid status.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No adjustment required for Child-Pugh Class A or B; use with caution in Class C due to potential fluid shifts and electrolyte imbalance; monitor closely.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Colonoscopy preparation for pediatric patients: 25 m L/kg/hour orally (maximum 1000 m L/hour) until rectal effluent is clear, up to 4 L total. For constipation: 0.5-1.5 g/kg/day orally divided once daily; max 17 g/day.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Start with lower doses for constipation (e.g., 7.5-10 g/day); ensure adequate hydration; monitor electrolytes and renal function due to age-related decline; use with caution in those with unstable blood pressure or cardiac conditions.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA boxed warning exists for this combination product, but individual components may have warnings.
None
Risk of serious fluid and electrolyte disturbances,Use caution in patients with renal impairment, cardiac disease, or electrolyte abnormalities,Avoid in patients with GI obstruction, perforation, or toxic colitis,May cause seizures due to electrolyte shifts (especially hyponatremia)
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis or megacolon,Hypersensitivity to any component,Severe electrolyte abnormalities (e.g., hypernatremia, hypokalemia)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid solid food during preparation; only clear liquids (e.g., water, clear broth, apple juice) allowed at least 2 hours before procedure. Do not consume red or purple liquids as they may be mistaken for blood. Avoid alcohol.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
PEG-3350, potassium chloride, sodium bicarbonate, and sodium chloride are not absorbed systemically in significant amounts; therefore, no fetal risk is anticipated. No teratogenic effects have been reported. For all trimesters, minimal to no risk.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
These agents are minimally absorbed; thus, excretion into breast milk is negligible. M/P ratio not determined. Considered compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustments required as pharmacokinetics are unchanged; bowel preparation protocols are the same as in non-pregnant patients.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Administer as a split-dose regimen for colonoscopy: first half evening before, second half morning of procedure. Ensure adequate hydration; monitor for electrolyte disturbances in patients with renal impairment or heart failure. Avoid in patients with ileus, gastric retention, or gastrointestinal obstruction. Can cause nausea and bloating; slow rate of ingestion helps. For powdery formulation, reconstitute exactly per instructions to avoid hypernatremia.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Take the medication exactly as prescribed, usually as a split dose for colonoscopy preparation.,Do not add any other ingredients to the solution.,Drink plenty of clear liquids during the preparation to stay hydrated.,You may experience bloating, cramping, or nausea; slow down your drinking if this occurs.,Do not eat solid food during the preparation; only clear liquids are allowed.,Stop drinking the solution at least 2 hours before your procedure.,Contact your doctor if you have severe abdominal pain, vomiting, or if you cannot keep the solution down.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE is a Electrolyte that works by Osmotic laxative: PEG-3350 retains water in stool via osmotic effect; electrolytes (potassium, sodium, bicarbonate) prevent electrolyte depletion and maintain fluid balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE is: Adult dose for colonoscopy preparation: 240 m L (1 glass) orally every 10 minutes until 4 L consumed or rectal effluent is clear. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water orally once daily, not to exceed 7 days.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE is classified as Category A/B. PEG-3350, potassium chloride, sodium bicarbonate, and sodium chloride are not absorbed systemically in significant amounts; therefore, no fetal risk is anticipated. No teratogenic . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.